search

John Chambers

Senior Manager, Health Economics & Advanced Analytics

A man wearing glasses, a dark suit, and a blue-and-white striped tie smiles in front of a textured beige wall.

John analyzes large healthcare… Health Economics & Advanced Analytics team who analyzes large healthcare data sets in support of clients across a variety of sectors, including the life sciences and healthcare industries. He applies advanced statistical and analytical techniques to yield actionable insights from the data, assisting clients in their mission to improve patient care and health outcomes, lower healthcare costs, and drive more effective business decision-making strategies.

Prior to joining Inovalon, John was a senior consultant at Deloitte where he led an analytics team involved in a large-scale government sector project to build a technological platform for the delivery, sharing, reporting, and analysis of public health and life event data. In addition, John previously worked as a data science consultant for AdventHealth System where he was responsible for analytics, reporting, and management of healthcare utilization and market data. Before entering the healthcare industry, John served as a university professor, conducting and publishing scientific research and teaching courses including statistics and research methods.

John holds a PhD in experimental psychology with a concentration in statistics from the University of Iowa.

Connect on LinkedIn
Authored Content
Placeholder
Neurology

Clinical and economic burden of breakthrough seizures

The purpose of this study was to measure healthcare resource utilization and costs in treatment-adherent, previously seizure-free patients with epilepsy...

Read More →
Placeholder
Neurology

Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: A retrospective U.S. claims database analysis

Achieving therapeutic goals in multiple sclerosis (MS) requires strict adherence to treatment schedules. This retrospective study analyzed persistence with, and...

Read More →
Placeholder
Neurology

Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: A U.S. claims database study

Approximately one-third of patients with multiple sclerosis (MS) are unresponsive to, or intolerant of, interferon (IFN) therapy, prompting a switch...

Read More →
Placeholder
Neurology

Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: A retrospective U.S. claims database analysis

Disease-modifying therapies, such as fingolimod, interferon (IFN) and glatiramer acetate (GA), have differing effects on relapse rates in patients with...

Read More →
Share